Benzodiazepines

Neurelis Announces Five Poster Presentations for the Annual Meeting of the American Academy Of Neurology

Retrieved on: 
Monday, April 19, 2021

In addition, the data shows that patients reported feeling like their usual self within two hours after VALTOCO administration.

Key Points: 
  • In addition, the data shows that patients reported feeling like their usual self within two hours after VALTOCO administration.
  • To be able to continue on with your day is very meaningful for patients with seizure clusters.
  • In a long-term, open-label, repeat-dose clinical trial, the safety of VALTOCO was evaluated, and more than 4,000 seizures were treated.
  • Serious and fatal adverse reactions, including "gasping syndrome", can occur in neonates and low-birth-weight infants treated with benzyl alcohol-preserved drugs, including VALTOCO.

DGAP-News: ​​​​​​​PAION AG REPORTS ON SUCCESSFUL FISCAL YEAR 2020

Retrieved on: 
Tuesday, March 30, 2021

Outstanding milestones were the first approvals of remimazolam in key pharma markets and the first successful launches by our partners.

Key Points: 
  • Outstanding milestones were the first approvals of remimazolam in key pharma markets and the first successful launches by our partners.
  • The associated milestone payments have led to a positive full-year result in 2020," commented Dr. Jim Phillips, CEO of PAION AG.
  • In Europe, remimazolam (trade name Byfavo(R)) is approved in procedural sedation and in addition PAION is seeking approval for general anesthesia.
  • In January 2020, PAION and Hana Pharm extended their license agreement for remimazolam to include Southeast Asia (Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam).

VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines

Retrieved on: 
Monday, March 22, 2021

PH94Bs MOA is, therefore, fundamentally differentiated from the MOA of benzodiazepines such as alprazolam, diazepam and lorazepam, which are direct GABA-A receptor positive modulators.

Key Points: 
  • PH94Bs MOA is, therefore, fundamentally differentiated from the MOA of benzodiazepines such as alprazolam, diazepam and lorazepam, which are direct GABA-A receptor positive modulators.
  • Among VistaGens core goals is for PH94B to displace these and other widely-used but highly-addictive benzodiazepines in the acute treatment paradigm for SAD and other anxiety disorders and phobias.
  • PH94B also has therapeutic potential in a wide range of additional anxiety disorders and phobias.
  • To help differentiate PH94Bs mechanism of action from that of benzodiazepines, VistaGen studied whether PH94B had positive modulatory effects on GABA receptors.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)

Retrieved on: 
Friday, March 12, 2021

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming April 30, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST ) securities between December 2, 2019 and September 25, 2020, inclusive (the Class Period).

Key Points: 
  • Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming April 30, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST ) securities between December 2, 2019 and September 25, 2020, inclusive (the Class Period).
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • Its most advanced proprietary product candidate is Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

DGAP-News: PAION GRANTS EXCLUSIVE LICENSE TO TTY BIOPHARM FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN TAIWAN

Retrieved on: 
Friday, March 5, 2021

Aachen (Germany), 05 March 2021 - PAION AG, a specialty pharma company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8), and TTY Biopharm Company Limited ("TTY") today announce that they have entered into a license agreement for remimazolam with PAION granting TTY an exclusive license for the development and commercialization of PAION's lead drug candidate, remimazolam, in Taiwan.

Key Points: 
  • Aachen (Germany), 05 March 2021 - PAION AG, a specialty pharma company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8), and TTY Biopharm Company Limited ("TTY") today announce that they have entered into a license agreement for remimazolam with PAION granting TTY an exclusive license for the development and commercialization of PAION's lead drug candidate, remimazolam, in Taiwan.
  • Under the terms of the agreement, TTY has the right and obligation to further develop remimazolam in all indications in Taiwan with PAION's support.
  • Dr. Jim Phillips, CEO of PAION AG, commented: "We are excited to have TTY as our partner for remimazolam in Taiwan.
  • Remimazolam, developed by PAION, has been approved in many countries and is a promising medicine for physicians and patients.

SHAREHOLDER ALERT: Robbins LLP Announces That Aquestive Therapeutics, Inc. (AQST) is Being Sued for Misleading Shareholders

Retrieved on: 
Thursday, March 4, 2021

Aquestive is a specialty pharmaceutical company that develops products to address unmet medical needs.

Key Points: 
  • Aquestive is a specialty pharmaceutical company that develops products to address unmet medical needs.
  • The Company's most advanced proprietary product candidate is Libervant (diazepam), the first oral diazepam-based therapy for the treatment of recurrent epileptic seizures.
  • If you suffered a loss due to Aquestive Therapeutics, Inc.'s misconduct, click here .
  • During the relevant period, Aquestive expressed that the process for obtaining FDA approval was on target and "as expected."

The Law Offices of Frank R. Cruz Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors

Retrieved on: 
Thursday, March 4, 2021

The Law Offices of Frank R. Cruz announces an investigation of Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST ) on behalf of investors concerning the Companys possible violations of federal securities laws.

Key Points: 
  • The Law Offices of Frank R. Cruz announces an investigation of Aquestive Therapeutics, Inc. (Aquestive or the Company) (NASDAQ: AQST ) on behalf of investors concerning the Companys possible violations of federal securities laws.
  • Aquestive is a specialty pharmaceutical company.
  • Its most advanced proprietary product candidate is Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

High Prescription of Psychoactive Class of Medicines for Mental Health Conditions spurs Growth in Benzodiazepine Drugs Market, Market Projected to touch Valuation of US$ 2.617 billion by 2026, TMR

Retrieved on: 
Thursday, March 4, 2021

Such extensive use of the drug is anticipated to fuel growth of the global benzodiazepine drugs market over the analysis timeline, from 2018 to 2026.

Key Points: 
  • Such extensive use of the drug is anticipated to fuel growth of the global benzodiazepine drugs market over the analysis timeline, from 2018 to 2026.
  • In 2017, the global benzodiazepine drugs market was estimated to be worth around US $ 2055 Mn.
  • The market is projected to clock a growth rate of 2.7 % CAGR over the assessment tenure, from 2018 to 2026.
  • The global benzodiazepine drugs market is being driven by an increase in the prevalence of anxiety and seizures.

High Prescription of Psychoactive Class of Medicines for Mental Health Conditions spurs Growth in Benzodiazepine Drugs Market, Market Projected to touch Valuation of US$ 2.617 billion by 2026, TMR

Retrieved on: 
Thursday, March 4, 2021

Such extensive use of the drug is anticipated to fuel growth of the global benzodiazepine drugs market over the analysis timeline, from 2018 to 2026.

Key Points: 
  • Such extensive use of the drug is anticipated to fuel growth of the global benzodiazepine drugs market over the analysis timeline, from 2018 to 2026.
  • In 2017, the global benzodiazepine drugs market was estimated to be worth around US $ 2055 Mn.
  • The market is projected to clock a growth rate of 2.7 % CAGR over the assessment tenure, from 2018 to 2026.
  • The global benzodiazepine drugs market is being driven by an increase in the prevalence of anxiety and seizures.

DGAP-News: PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS

Retrieved on: 
Thursday, January 28, 2021

PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS

Key Points: 
  • PAION AG: ACACIA PHARMA LAUNCHES BYFAVO(TM) (REMIMAZOLAM) IN THE U.S. FOR PROCEDURAL SEDATION IN ADULTS UNDERGOING MEDICAL PROCEDURES LASTING 30 MINUTES OR LESS
    The issuer is solely responsible for the content of this announcement.
  • BYFAVO(TM) was approved by the U.S. Food and Drug Administration (FDA) on 2 July 2020 for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.
  • Remimazolam is approved in the U.S. and China for procedural sedation and in Japan and South Korea for general anesthesia.
  • In Europe, PAION submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in procedural sedation in November 2019.